

12 May 2016

Exclusive Engagement Signed with OHC for Scandinavian Territories

Highlights

- Respected consultant, Oskar Hakansson, engaged to actively negotiate distribution agreements in Scandinavian territories
- Omniblend Innovation retains final approval on any negotiated agreements
- No upfront fees to Omniblend Innovation for engagement of negotiator

EVE Investments (ASX:EVE), an ASX-listed technology investment company, is pleased to provide an update on Omniblend Innovation, the medical technology company focused on foods for special medical purposes, in which EVE holds a ~25% interest, increasing to a ~40% holding by 30 September 2016. Omniblend Innovation (“OI”) has engaged Oskar Hakansson Consulting (“OHC”) to provide Omniblend Innovation with assistance in licensing opportunities in Scandinavian countries.

Engagement with OHC

OHC has been engaged to identify, negotiate and contract exclusive supply of Omniblend Innovation’s clinically-validated natural pre-meal drink for those with type 2 diabetes (T2D) and pre-diabetes, known in Australia as Faulding GlucoControl™, with partners and distributors in Sweden, Denmark, Norway and Finland for an exclusive period of two years. According to estimates prepared by OHC there is approximately one million people in Scandinavia who are living with type 2 diabetes.

About EVE Investments

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in technology companies. With a preference for companies that have global scale, EVE is an investment partner that wants to help build ground breaking and enduring technology.

For more information, please visit www.eveinvestments.com.au and follow us on Twitter @EVEInvestments